^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Imdelltra (tarlatamab-dlle)

i
Other names: AMG 757, AMG757, AMG-757
Company:
Amgen, BeiGene
Drug class:
CD3 agonist, DLL3 inhibitor
Related drugs:
4d
DeLLphi-300: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P1, N=269, Active, not recruiting, Amgen | Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2024 --> Apr 2025
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • Imdelltra (tarlatamab-dlle)
7d
Recent advances in immunotherapy for small cell lung cancer. (PubMed, Curr Opin Oncol)
Despite the improved outcomes associated with immunotherapy in SCLC, the overall clinical benefit remains modest. Further preclinical and clinical studies are essential to identify optimal treatment regimens and enhance therapeutic efficacy.
Journal • IO biomarker
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
Imdelltra (tarlatamab-dlle)
7d
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer. (PubMed, Future Oncol)
The study found that tarlatamab given every 2 weeks shrank SCLC in participants with SCLC who received previous treatments. Participants given the 10 mg tarlatamab dose had fewer side effects than those given the 100 mg tarlatamab dose.Clinical Trial Registration: NCT05740566 (DeLLphi-304) (ClinicalTrials.gov).
Journal
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
Imdelltra (tarlatamab-dlle)
29d
DeLLpro-300: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov)
P1, N=41, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Jul 2024 | Trial primary completion date: Aug 2025 --> Jul 2024
Trial completion • Trial completion date • Trial primary completion date
|
Imdelltra (tarlatamab-dlle)
30d
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P1, N=23, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024
Trial completion • Trial completion date • Combination therapy
|
Imdelltra (tarlatamab-dlle) • zeluvalimab (AMG 404)
1m
Enrollment open
|
Imdelltra (tarlatamab-dlle)
1m
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Amgen | Phase classification: P1b --> P1
Phase classification • Combination therapy
|
Imdelltra (tarlatamab-dlle) • zeluvalimab (AMG 404)
1m
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer. (PubMed, Curr Treat Options Oncol)
Before the approval of Tarlatamab-dlle, only a few drugs, such as Atezolizumab and Durvalumab, received FDA approval for treating extensive-stage SCLC. It might be possible that Tarlatamab-dlle received accelerated FDA approval for extensive-stage SCLC, leaving some questions unanswered at this stage. This manuscript is focused on clinical, pre-clinical, and other pharmacological aspects of Tarlatamab-dlle for extensive-stage SCLC.
Review • Journal
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle)
2ms
Enrollment open
|
Imdelltra (tarlatamab-dlle)
2ms
DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov)
P1, N=184, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=340 --> 184 | Trial completion date: Jun 2029 --> Aug 2028 | Trial primary completion date: Jun 2029 --> Aug 2028
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle)
2ms
New P1 trial
|
Imdelltra (tarlatamab-dlle)
2ms
DeLLphi-301: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P2, N=222, Active, not recruiting, Amgen | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date
|
Imdelltra (tarlatamab-dlle)
4ms
Enrollment closed
|
topotecan • Zepzelca (lurbinectedin) • Imdelltra (tarlatamab-dlle) • Calsed (amrubicin)
4ms
DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov)
P1, N=340, Recruiting, Amgen | Trial completion date: Jan 2027 --> Jun 2029 | Trial primary completion date: Jan 2027 --> Jun 2029
Trial completion date • Trial primary completion date • Combination therapy
|
Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle)
4ms
Enrollment change
|
Keytruda (pembrolizumab) • Imdelltra (tarlatamab-dlle)
4ms
Tarlatamab: First Approval. (PubMed, Drugs)
Tarlatamab is under regulatory review in Brazil, Canada, Israel and the UK, and clinical studies are underway in multiple countries. This article summarizes the milestones in the development of tarlatamab leading to this first approval for ES-SCLC with disease progression on or after platinum-based chemotherapy.
Review • Journal
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
Imdelltra (tarlatamab-dlle)
4ms
Enrollment closed
|
Keytruda (pembrolizumab) • Imdelltra (tarlatamab-dlle)
5ms
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients. (PubMed, Mol Oncol)
Specific tumor biomarkers, such as delta-like ligand 3 (DLL3) and schlafen11 (SLFN11), may enable the selection of more efficacious, novel immunomodulating targeted treatments like bispecific T-cell engaging monoclonal antibodies (tarlatamab) and chemotherapy with PARP inhibitors...CTCs have been studied for their prognostic ability in SCLC; however, their value in guiding treatment decisions is yet to be elucidated. This review explores novel and promising targeted therapies in SCLC, summarizes current knowledge of CTCs in SCLC, and discusses how CTCs can be utilized for precision medicine.
Review • Journal • Circulating tumor cells • PARP Biomarker • IO biomarker • Tumor cell
|
SLFN11 (Schlafen Family Member 11) • DLL3 (Delta Like Canonical Notch Ligand 3)
|
Imdelltra (tarlatamab-dlle)
5ms
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics. (PubMed, Genes (Basel))
Moreover, SCLC can also develop intratumoral heterogeneity linked mainly to the concept of cellular plasticity, mostly due to the development of resistance to therapies. The aim of this review is to quickly present the current standard of care of ES-SCLC, to focus on the molecular landscapes and subtypes of SCLC, subsequently present the most promising therapeutic strategies under investigation, and finally recap the future directions of ongoing clinical trials for this aggressive disease which still remains a challenge.
Review • Journal • IO biomarker
|
TP53 (Tumor protein P53)
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle)
5ms
DLL3 Expression In Early—Stage SCLC: Comparative Analysis Of IHC and mRNA ISH (LUNG-SPORE 2024)
"Tarlatamab, targeting DLL3 and CD3, showed a 40% response rate in previously treated patients... In 248 early-stage SCLC, positivity for DLL3 was 58% with IHC and 87% with mRNA ISH. A trend for improved survival in patients with no DLL3 expression was observed. Future studies on DLL3 might improve SCLC treatment SCLC."
VENTANA DLL3 (SP347) Assay
|
Imdelltra (tarlatamab-dlle)
5ms
Enrollment open • Combination therapy
|
Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle)
6ms
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. (PubMed, Mol Cancer)
Although rovalpituzumab tesirine (Rova-T) showed promise in a phase II study, it failed to produce favorable results in subsequent phase III trials, leading to the cessation of its development...Tarlatamab, for instance, demonstrated enhanced response rates and progression-free survival compared to the standard of care in a phase II trial; its biologics license application (BLA) is currently under US Food and Drug Administration (FDA) review...DLL3-targeted therapies hold substantial potential for SCLC management. Future clinical trials will be crucial for comparing treatment outcomes among various approaches and exploring combination therapies to improve patient survival outcomes.
Journal
|
DLL3 (Delta Like Canonical Notch Ligand 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
|
Rova-T (rovalpituzumab tesirine) • Imdelltra (tarlatamab-dlle)
7ms
Trial primary completion date • Combination therapy
|
Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle)
7ms
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). (ASCO 2024)
Findings from this phase 1 study of tarlatamab in pts with NEPC demonstrated manageable safety with encouraging anti-tumor activity in DLL3 expressing NEPC. Further investigation is ongoing.
P1 data • IO biomarker
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
VENTANA DLL3 (SP347) Assay
|
Imdelltra (tarlatamab-dlle)
8ms
DeLLpro-300: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov)
P1, N=41, Active, not recruiting, Amgen | Phase classification: P1b --> P1 | Trial primary completion date: Mar 2023 --> Aug 2025
Phase classification • Trial primary completion date
|
Imdelltra (tarlatamab-dlle)
8ms
Enrollment open
|
Imdelltra (tarlatamab-dlle)
9ms
DeLLphi-301: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P2, N=222, Active, not recruiting, Amgen | Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Oct 2024
Trial completion date • Trial primary completion date
|
Imdelltra (tarlatamab-dlle)
9ms
DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=490, Recruiting, Amgen | N=700 --> 490 | Trial primary completion date: Sep 2025 --> Aug 2027
Enrollment change • Trial primary completion date
|
topotecan • Zepzelca (lurbinectedin) • Imdelltra (tarlatamab-dlle) • Calsed (amrubicin)
9ms
DeLLphi-306: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
P3, N=400, Not yet recruiting, Amgen | Trial primary completion date: Jul 2028 --> Oct 2029
Trial primary completion date
|
Imdelltra (tarlatamab-dlle)
10ms
Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel. (PubMed, Cancers (Basel))
Tarlatamab is a novel promising therapeutic antibody currently under investigation for its potential use in previously treated SCLC patients. This mini-review will explore the current state of second-line treatment options for SCLC, their clinical efficacy, and future directions.
Journal
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
Imdelltra (tarlatamab-dlle)
10ms
New P3 trial • Combination therapy
|
Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle)
11ms
DeLLphi-306: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
P3, N=400, Not yet recruiting, Amgen | Trial primary completion date: Oct 2026 --> Jul 2028
Trial primary completion date
|
Imdelltra (tarlatamab-dlle)
11ms
Trial primary completion date
|
topotecan • Zepzelca (lurbinectedin) • Imdelltra (tarlatamab-dlle) • Calsed (amrubicin)
11ms
Trial completion date
|
Keytruda (pembrolizumab) • Imdelltra (tarlatamab-dlle)
12ms
Phase classification
|
Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle)
1year
New P3 trial
|
Imdelltra (tarlatamab-dlle)
1year
Trial completion date
|
Keytruda (pembrolizumab) • Imdelltra (tarlatamab-dlle)
1year
DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov)
P1b, N=340, Recruiting, Amgen | Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Nov 2024 --> Dec 2025
Trial completion date • Trial primary completion date • Combination therapy
|
Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle)
1year
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P1b, N=23, Active, not recruiting, Amgen | Trial completion date: Jan 2026 --> Jan 2025
Trial completion date • Combination therapy
|
Imdelltra (tarlatamab-dlle) • zeluvalimab (AMG 404)
1year
Trial completion date
|
Keytruda (pembrolizumab) • Imdelltra (tarlatamab-dlle)
1year
Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models (SITC 2023)
While treatment with platinum and etoposide chemotherapy and a programmed death-ligand 1 (PD-L1) inhibitor has modest benefit for a subset of patients, most patients develop resistance and relapse. The increased cytotoxic activity observed with the combination of tarlatamab and chemotherapy and/or anti-PD-L1 treatment suggests that tarlatamab may be used together with standard of care therapy to increase response rate or durability. These data support the continued clinical evaluation of tarlatamab in patients with SCLC, including in combination with chemo-immune therapy in the first-line setting.
Preclinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
PD-L1 expression • DLL3 expression
|
etoposide IV • Imdelltra (tarlatamab-dlle)